** Shares of drug developer ATX.AX rise as much as 2.9% to
A$0.180, mark their biggest intraday pct gain since Nov 24
** Amplia Therapeutics says application for a non-dilutive
funding facility as part of the Victorian govt's R&D cash flow
loan initiative has been approved urn:newsml:reuters.com:*:nASX2bYDFF
** Co says the facility will provide a maximum of A$2.1 mln
($1.49 mln) awarded in two tranches: A$1.3 mln in Dec and A$0.8
mln in the quarter ending March 2022
** Adds that funds from loan facility will be used to
evaluate and prepare activities to support future clinical
trials of co's second Focal Adhesion Kinase inhibitor, AMP886
** More than 236,240 shares change hands, compared with the
30-day average volume of 170,210 shares
** Stock down 26.3% this year, as of last close
($1 = 1.4059 Australian dollars)
(Reporting by Roushni Nair in Bangalore)
((Roushni.Nair@thomsonreuters.com))